CAYSTON POWDER FOR SOLUTION
Land: Canada
Språk: engelsk
Kilde: Health Canada
Preparatomtale
(SPC)
15-05-2020
Noen dokumenter for dette produktet er ikke tilgjengelig for øyeblikket, du kan sende en forespørsel til kundeservicen vår, og vi vil varsle deg så snart vi kan få dem.
Send forespørsel.
Send forespørsel.
Aktiv ingrediens:
AZTREONAM
Tilgjengelig fra:
GILEAD SCIENCES CANADA INC
ATC-kode:
J01DF01
INN (International Name):
AZTREONAM
Dosering :
75MG
Legemiddelform:
POWDER FOR SOLUTION
Sammensetning:
AZTREONAM 75MG
Administreringsrute:
INHALATION
Enheter i pakken:
2ML
Resept typen:
Prescription
Terapeutisk område:
MONOBACTAMS
Produkt oppsummering:
Active ingredient group (AIG) number: 0122819004; AHFS:
Autorisasjon status:
APPROVED
Autorisasjon dato:
2009-09-11
Preparatomtale
PRODUCT MONOGRAPH
PR
CAYSTON
®
AZTREONAM FOR INHALATION SOLUTION
75 MG AZTREONAM / VIAL
ANTIBIOTIC
_(ATC J01DF01) _
_ _
_ _
_ _
_ _
_ _
Gilead Sciences, Inc.
Foster City, CA 94404
USA
Gilead Sciences Canada, Inc.
Mississauga, ON
L5N 2W3
www.gilead.ca
Control No.: 234938_ _
Date of Revision:
May 15, 2020
CAYSTON
(aztreonam for inhalation solution)
Product Monograph
2
TABLE OF CONTENTS
PART I.
HEALTH PROFESSIONAL INFORMATION
................................................................................
3
SUMMARY PRODUCT INFORMATION
..................................................................................................
3
INDICATIONS AND CLINICAL USE
........................................................................................................
3
CONTRAINDICATIONS
.............................................................................................................................
3
WARNINGS AND PRECAUTIONS
............................................................................................................
4
ADVERSE REACTIONS
..............................................................................................................................
6
DRUG INTERACTIONS
..............................................................................................................................
9
DOSAGE AND ADMINISTRATION
........................................................................................................
10
OVERDOSAGE
..........................................................................................................................................
11
ACTION AND CLINICAL PHARMACOLOGY
.......................................................................................
11
STORAGE AND STABILITY
....................................................................................................................
12
SPECIAL HANDLING
INSTRUCTIONS..................................................................................................
13
DOSAGE F
Les hele dokumentet
